Earlier this week, Dr. James Allison and Dr. Tasuku Honjo were announced as joint winners of the 2018 Nobel Prize in Physiology or Medicine for their work in the field of immunotherapy and checkpoint immune regulation. Their studies have sparked decades of clinical advances, and changed the future of cancer therapy. A webinar presented by Dr. Allison in conjunction with Dr. Gordon Freeman and Dr. Philip Gotwals is featured in this week's blog post.
Targeting Cancer Pathways: Understanding Immune Checkpoints webinar
In this webinar, we explore how tumors exploit immune modulatory mechanisms to generate and thrive in their own immunosuppressive microenvironment. Further, we examine how these mechanisms can be targeted to develop better therapeutic options. This webinar also includes:
- A historical overview of immune checkpoint research and examination of the effect of mutational load on clinical response.
- Explanation of how PD-1 immunotherapy stops certain cancers from turning off the anticancer immune response.
- Discussion of general therapeutic approaches to activating the immune system to treat cancer.
Interested in exploring Immune Checkpoint Signaling? Check out this interactive pathway:
